Medication info

K-Heparin Injection 20000 Units (Heparin Sodium)

Prescription medicationInjectionsIntravenous injection · Subcutaneous injection
Ingredient · strength
Heparin Sodium›Strength being verified
Manufacturer / importer
Kips Biopharma Co., Ltd.
Appearance
A transparent liquid ranging from colorless to pale yellow, contained in brown glass vials.
Packaging
20 milliliters × 10 vials
Approval status
Active

MFDS item code 201601133 · Notified 2016.02.29 · Insurance code 693201691

Summary

Main use
Treatment and prevention of thrombotic and embolic disorders; diagnosis and treatment of coagulation disorders; inhibition of blood coagulation
Who receives it
Adults
Adult administration
This medication is usually administered by intravenous injection or added to the perfusate during extracorporeal blood circulation. It takes effect immediately after administration; however, heparin sensitivity varies considerably among individuals. Therefore, perform a heparin sensitivity test before administration, and determine the maintenance dose by measuring blood clotting time after administration. Blood clotting time is usually maintained at 15 ~ 20 minutes or longer after administration, but the dose should be determined according to the case, indication, and purpose of treatment. 1. Extracorporeal circulation 1) Artificial kidney (1) Systemic heparinization: Administer 1,000 ~ 5,000 IU of heparin sodium before starting dialysis, and after dialysis begins, administer 500 ~ 1,500 IU per hour continuously or intermittently every hour. (2) Regional heparinization: Administer 1,500 ~ 2,500 IU per hour continuously, and neutralize with protamine sulfate during extracorporeal perfusion. 2) Blood perfusion using a heart-lung machine : Administer 150 ~ 300 IU per kg of body weight, and add more as appropriate if the duration of extracorporeal circulation is prolonged. After extracorporeal circulation, use protamine sulfate to prevent postoperative bleeding and neutralize the effects of heparin. 2. Intravenous infusion Dissolve 10,000 ~ 30,000 IU of this medication in 1,000 mL of 5 % dextrose injection, normal saline injection, or Ringer's solution, and infuse at a rate of approximately 30 drops per minute. When whole blood clotting time reaches 2 ~ 3 times the pretreatment value, continue infusion at approximately 20 drops per minute. 3. Intermittent intravenous injection Administer 5,000 ~ 10,000 IU intravenously every 4 ~ 8 hours. Beginning 3 hours after initiation of treatment, measure whole blood clotting time every 2 ~ 4 hours and adjust the dose to achieve 2 ~ 3 times the pretreatment value. 4. Subcutaneous injection Administer 10,000 ~ 20,000 IU subcutaneously, followed by a maintenance dose of 15,000 ~ 20,000 IU every 12 hours. Change the injection site each time to prevent hematoma. 5. Blood transfusion and blood tests For blood transfusion, use 400 ~ 500 IU of this medication per 100 mL of blood; for blood tests, use 100 IU per 20 ~ 30 mL of blood.

Ingredients

Manufacturer
Kips Biopharma Co., Ltd.

Efficacy & effects

Treatment and prevention of thrombotic and embolic disorders; diagnosis and treatment of coagulation disorders; inhibition of blood coagulation

  • Thrombosis
  • pulmonary embolism
  • embolic atrial fibrillation
  • acute coagulation disorders
  • chronic coagulation disorders
  • blood coagulation
  • cerebral thrombosis
  • coronary artery occlusion
  • peripheral vascular embolism
View approved original text

This medication is used for the prevention and treatment of thrombosis and pulmonary embolism. It also prevents thrombus formation due to embolic atrial fibrillation and is effective for acute and chronic coagulation disorders. It is utilized to prevent blood coagulation during and after surgical procedures, including vascular and cardiac surgeries. It helps in preventing cerebral thrombosis due to cerebral hemorrhage and inhibits blood coagulation during transfusions, extracorporeal circulation, and dialysis. It is used for the prevention and treatment of coronary artery occlusion and peripheral vascular embolism. This drug improves blood coagulation issues and treats various thrombotic-related diseases.

How it is given

Adult administration

This medication is usually administered by intravenous injection or added to the perfusate during extracorporeal blood circulation. It takes effect immediately after administration; however, heparin sensitivity varies considerably among individuals. Therefore, perform a heparin sensitivity test before administration, and determine the maintenance dose by measuring blood clotting time after administration. Blood clotting time is usually maintained at 15 ~ 20 minutes or longer after administration, but the dose should be determined according to the case, indication, and purpose of treatment. 1. Extracorporeal circulation 1) Artificial kidney (1) Systemic heparinization: Administer 1,000 ~ 5,000 IU of heparin sodium before starting dialysis, and after dialysis begins, administer 500 ~ 1,500 IU per hour continuously or intermittently every hour. (2) Regional heparinization: Administer 1,500 ~ 2,500 IU per hour continuously, and neutralize with protamine sulfate during extracorporeal perfusion. 2) Blood perfusion using a heart-lung machine : Administer 150 ~ 300 IU per kg of body weight, and add more as appropriate if the duration of extracorporeal circulation is prolonged. After extracorporeal circulation, use protamine sulfate to prevent postoperative bleeding and neutralize the effects of heparin. 2. Intravenous infusion Dissolve 10,000 ~ 30,000 IU of this medication in 1,000 mL of 5 % dextrose injection, normal saline injection, or Ringer's solution, and infuse at a rate of approximately 30 drops per minute. When whole blood clotting time reaches 2 ~ 3 times the pretreatment value, continue infusion at approximately 20 drops per minute. 3. Intermittent intravenous injection Administer 5,000 ~ 10,000 IU intravenously every 4 ~ 8 hours. Beginning 3 hours after initiation of treatment, measure whole blood clotting time every 2 ~ 4 hours and adjust the dose to achieve 2 ~ 3 times the pretreatment value. 4. Subcutaneous injection Administer 10,000 ~ 20,000 IU subcutaneously, followed by a maintenance dose of 15,000 ~ 20,000 IU every 12 hours. Change the injection site each time to prevent hematoma. 5. Blood transfusion and blood tests For blood transfusion, use 400 ~ 500 IU of this medication per 100 mL of blood; for blood tests, use 100 IU per 20 ~ 30 mL of blood.

Precautions

This medication is very potent and should be used only under the strict supervision of a physician. Caution is especially required for patients with diseases that carry a high risk of bleeding, as bleeding may occur in almost any part of the body during its administration. It should not be used in premature infants, such as underweight babies, as benzyl alcohol contained in this drug can cause life-threatening respiratory issues. It should not be administered to patients with allergies to this drug or its components, abnormal blood coagulation function, existing bleeding, severe liver or kidney diseases, etc. It should also be avoided in patients who have undergone central nervous system surgery or spinal anesthesia. Special care should be taken when administering it to late-pregnancy women, children, the elderly, and patients with specific diseases while closely monitoring their blood coagulation status. Use of this medication may cause bleeding, thrombocytopenia, liver dysfunction, allergic reactions, skin issues, local pain, etc.; any unusual symptoms should be reported to a healthcare professional immediately. Regular blood coagulation tests should be conducted to manage the risk of bleeding, and administration should be stopped or adjusted as needed. If platelet counts drop sharply, this medication should be discontinued immediately, and further tests should be performed. Co-administration with other medications may increase bleeding risk; caution is warranted, especially with aspirin, non-steroidal anti-inflammatory drugs, anticoagulants, etc. Women who are pregnant or breastfeeding should use this medication with caution, considering its effects on the fetus and neonate, particularly regarding the risk of bleeding during childbirth. In cases of overdose, bleeding complications may arise, and the antidote protamine sulfate should be administered immediately, while remaining aware of severe side effects that may arise even when using the antidote. Muscle injections should be avoided due to the risk of hematoma, and this medication should not be mixed with antihistamines for injection.

Side effects

Bleeding, fatal bleeding, acute adrenal insufficiency, adrenal hemorrhage, ovarian hemorrhage, retroperitoneal hemorrhage, thrombocytopenia, arterial and venous thrombosis, acute reversible thrombocytopenic syndrome, elevated γ-GTP, elevated LDH, elevated AST, elevated ALT, itching, urticaria, chills, fever, rhinitis, bronchial asthma, tearing, conjunctivitis, cyanosis, tachycardia, sense of pressure, angioedema, nausea, vomiting, hypotension, shortness of breath, bronchospasm, shock, hair loss, vitiligo, hemorrhagic necrosis, hypoaldosteronism, osteoporosis, rebound effect, dyslipidemia, renal function suppression, localized painful hematoma, priapism, diabetes, hyperkalemia, hyperalkalemia, metabolic acidosis, elevated lipase, vascular spastic reaction, erythema, mild pain, ulcer

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light, so it should be stored in a tightly sealed container protected from light. The storage temperature should ideally be maintained between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

A transparent liquid ranging from colorless to pale yellow, contained in brown glass vials.

Package unit

20 milliliters × 10 vials

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.